Publications by authors named "Erkan Kayikcioglu"

Claim this Profile
R
Refining risk stratification in PSMA-PET guided salvage radiotherapy: methodological and translational considerations.
Asim Armagan Aydin, Erkan Kayikcioglu

Radiother Oncol· January 2026

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Gustave Roussy immune score as a novel biomarker for predicting survival in patients with isocitrate dehydrogenase wild-type glioblastoma treated with the Stupp protocol.
Asim Armagan Aydin, Ahmet Unlu, Neslihan Atabek, Erkan Kayikcioglu, Kamuran Yuceer

Expert Rev Anticancer Ther· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Subcutaneous pertuzumab-trastuzumab: Efficiency, safety, and the biosimilar horizon.
Asim Armagan Aydin, Erkan Kayikcioglu

Breast· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Minimally Invasive Surgery Versus SABR in Stage IA NSCLC: Interpreting Real-World Evidence with Caution.
Asim Armagan Aydin, Erkan Kayikcioglu

Clin Lung Cancer· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Beyond BMI: Metabolic and Inflammatory Determinants of Recurrence After Neoadjuvant Therapy in Breast Cancer.
Asim Armagan Aydin, Erkan Kayikcioglu

Clin Breast Cancer· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessment of polypharmacy, potentially inappropriate medications, and drug-drug interactions in older patients with cancer.
Aslınur Albayrak, Bahar Erbay, Erkan Kayıkçıoğlu

J Oncol Pharm Pract· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world data on the efficacy and safety of trastuzumab emtansine in patients with metastatic breast cancer previously treated with pertuzumab: Turkish oncology group multicenter study.
Özgecan Dülgar, Sema Türker, Gül Başaran, Murat Araz, Ahmet Taner Sümbül

J Chemother· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-World Treatment Efficacy of Ribociclib or Palbociclib Plus Fulvestrant in Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer: Turkish Oncology Group (TOG) Study.
Seda Kahraman, Enes Erul, Ozge Gumusay, Deniz Can Guven, Sercan Aksoy, Erkan Kayikcioglu

Clin Breast Cancer· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cancer Patients' Attachment Styles in the First Year After Diagnosis: The Impact of Perceived Stress and Emotion Regulation Skills.
Gözde Bacık Yaman, Erkan Kayıkçıoğlu, Çiçek Hocaoğlu

Psychiatry Clin Psychopharmacol· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of first-line CDK 4-6 inhibitors in premenopausal patients with metastatic breast cancer and the effect of dose reduction due to treatment-related neutropenia on efficacy: a Turkish Oncology Group (TOG) study.
Hasan Cagri Yildirim, Caner Kapar, Baris Koksal, Mustafa Seyyar, Pervin Can Sanci, Erkan Kayikcioglu

J Chemother· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Prognostic Significance of CD47, CD68, and CD163 Expression Levels and Their Relationship with MLR and MAR in Locally Advanced and Oligometastatic Nasopharyngeal Carcinoma.
Asim Armagan Aydin, Ramazan Oguz Yuceer, Senay Yildirim, Ahmet Unlu, Erkan Kayikcioglu

Diagnostics (Basel)· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pan-Immune-Inflammation Value as a Novel Prognostic Biomarker for Advanced Pancreatic Cancer.
Asim Armagan Aydin, Erkan Kayikcioglu, Ahmet Unlu, Mehmet Acun, Halil Goksel Guzel

Cureus· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Machine learning for predicting colon cancer recurrence.
Erkan Kayikcioglu, Arif Hakan Onder, Burcu Bacak, Tekin Ahmet Serel

Surg Oncol· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The efficacy of palbociclib and ribociclib in the first-line treatment of metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer in male patients: a Turkish oncology group (TOG) study.
Hasan Çağrı Yıldırım, Yasin Kutlu, Emel Mutlu, Musa Barış Aykan, Mustafa Korkmaz

Int J Clin Oncol· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic value of computed tomography associated body composition measurement changes in metastatic colorectal cancer patients.
Zekai Emre Sevgilioglu, Sehnaz Evrimler, Gokce Iscan, Erkan Kayikcioglu, Sevim Sureyya Sengul

Acta Radiol· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Potential drug-drug interactions in patients with non-small cell lung cancer at a university hospital in Turkey.
Aslınur Albayrak, Tuğdenur Düzenli, Erkan Kayıkçıoğlu

J Cancer Res Clin Oncol· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment efficacy of ribociclib or palbociclib plus letrozole in hormone receptor-positive/HER2-negative metastatic breast cancer.
Seda Kahraman, Enes Erul, Mustafa Seyyar, Ozge Gumusay, Ertugrul Bayram, Erkan Kayikcioglu

Future Oncol· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapy.
Cengiz Karacin, Berna Oksuzoglu, Ayşe Demirci, Merve Keskinkılıç, Naziyet Köse Baytemür

BMC Cancer· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The role of claudin 18.2 and HER-2 in pancreatic cancer outcomes.
Erkan Kayikcioglu, Ramazan Oğuz Yüceer

Medicine (Baltimore)· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction: Efficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapy.
Cengiz Karacin, Berna Oksuzoglu, Ayşe Demirci, Merve Keskinkılıç, Naziyet Köse Baytemür

BMC Cancer· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic value of claudin 18.2 expression in gastric adenocarcinoma.
Erkan Kayikcioglu, Ramazan Oğuz Yüceer, Bulent Cetin, Kamuran Yüceer, Nermin Karahan

World J Gastrointest Oncol· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Novel Prognostic Index for Metastatic Colon Cancer: The Prognostic Immune Nutritional Index.
Erkan Kayikcioglu, Gokce Iscan

Cureus· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis